Same class, two different molecules, four brand names between them. The comparison that matters is not which produced the bigger number in a trial, but which one suits your history, your tolerance and what you can actually get and afford.
Semaglutide is sold as Ozempic, approved for type 2 diabetes, and as Wegovy, approved for weight management. There is also a daily oral tablet. Same molecule, different approved uses and different dose ranges.
Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for weight management. It is the newer of the two and works on two gut hormones rather than one, GLP-1 and GIP.
This is the single most common confusion people arrive with, and it is worth clearing up first, because "is Ozempic better than Wegovy" is not really a question once you know they contain the same drug. Related reading: Semaglutide, Tirzepatide and Oral GLP-1 tablets.
Brand vs molecule
How the choice is made
Choosing between semaglutide and tirzepatide
History first
Some histories rule out one or both. Personal and family history, existing conditions and current medication all narrow the field before preference enters it.
Tolerance
Digestive side effects differ between people more than between molecules. Someone who cannot tolerate one may do well on the other, and switching is a normal step.
Cost and coverage
Price and what a drug plan will fund differ by product. A molecule you cannot afford to stay on is not the better option for you.
Availability
Supply of these products has been uneven. What is actually obtainable is part of the decision rather than a footnote to it.
What trials show
What the head-to-head data does and does not say
In direct comparison, tirzepatide produced greater average weight loss than semaglutide. That is a real finding and it is the reason tirzepatide gets asked for by name.
An average is not a prediction for one person. Trial populations are selected, adherence is supported, and the spread around any average is wide. A molecule you tolerate and stay on will out-perform a statistically superior one you stop after eight weeks. See Weight loss timeline, Common side effects and Dosing and titration for the rest of it.
GLP-1 onlySemaglutide
GLP-1 and GIPTirzepatide
Weekly injectionBoth
Read next
After the semaglutide vs tirzepatide comparison
The individual medication pages, and what each one costs.
Which is stronger, whether you can switch, and how cost enters the decision.
In head-to-head trial data tirzepatide produced greater average weight loss. Whether it is the better choice for you depends on tolerance, your history, cost and availability, none of which a trial average accounts for.
Yes, and it is a normal adjustment rather than a restart from zero. Switching is usually considered when side effects are not manageable or results have plateaued, and it is done with a fresh titration.
Both contain semaglutide. Ozempic is approved for type 2 diabetes and Wegovy for weight management, at different dose ranges. The drug is the same; the approval and the dosing are not.
Both contain tirzepatide, with Mounjaro approved for type 2 diabetes and Zepbound for weight management. Same pattern as semaglutide.
You can, and it will be discussed properly. The prescribing decision remains clinical, and there are histories where one or both are not appropriate regardless of preference.
Austin patients
What Austin patients say about choosing a molecule
Started on one, could not tolerate it past the second step, moved to the other and it was fine. Treated as routine rather than a problem.
E. Delacroix
Switched molecule, Austin
★★★★★
I came in convinced I needed the newer one. Ended up on the other for coverage reasons and it has worked. The reasoning was explained rather than asserted.
I. Karlsson
Comparison, Leander
★★★★
Honest that the trial difference is an average, not a promise. That framing was more useful than the numbers.
O. Mensah
Consultation, Cedar Park
★★★★★
Finally understood that two of the four names I had been researching were the same drug.
